Q32 Bio reports 35.3% mean SALT score reduction for bempikibart at 36 weeks
QTTB•Q32 Bio reported a 35.3% mean SALT score reduction at Week 36 in Part B of its Phase 2a SIGNAL-AA trial of bempikibart for severe alopecia areata. The company said the results support plans to start a registration-directed program in the first half of 2027.
1. Week 36 results
Q32 Bio disclosed additional Week 36 results from Part B of its Phase 2a SIGNAL-AA trial of bempikibart in severe alopecia areata. The data showed a 35.3% mean SALT score reduction; the company said safety was generally well tolerated, with no new safety signals.
